

EXPRESS MAIL CERTIFICATE

Date 7/20/98 **4 45427510**
I hereby certify that, on the date indicated above I
deposited this paper or fee with the U.S. Postal Service
and that it was addressed for delivery to the Commissioner
of Patents & Trademarks, Washington, DC 20231 by "Express
Mail Post Office to Addressee" service.

Name (Print)

Signature

11/2
RECEIVED

JUL 24 1998

MAIL ROOM
SERVICE CENTER

2055/0E203

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: David C. WATKINS et al.

Serial No.: 08/594,175

Group Art Unit: 1615

Filed: 01/31/96

Examiner: GOLLAMUDI KISHORE

For: LIPID VESICLES FORMED WITH ALKYLAMMONIUM FATTY ACID SALTS

July 20, 1998

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with the disclosure duty under 37 CFR §§ 1.56 and 1.97, the
documents listed below and on the accompanying PTO-1449 form are enclosed.¹ These

¹ If a listed document is not in the English language and an English translation is readily available, such translation is also enclosed and attached to the copy of the document. If a translation is not attached, it is not readily available to the undersigned. If a foreign language patent document is cited, and an English language equivalent is known to the undersigned, then the English equivalent patent is also listed on the enclosed form along with the corresponding foreign language patent and a connecting arrow indicates the relationship

documents contain information which the Examiner may consider to be important in deciding whether to allow the present application to issue as a patent:

1. USP 4,761,288, filed 08/02/88 (Mezei)
2. USP 5,296,231, filed 03/22/94 (Yarosh)
3. USP 4,897,269, filed 01/30/90 (Mezei)
4. USP 2,650,165, filed 08/25/53 (Wahl)
5. USP 4,032,663, filed 06/28/77 (Kobayashi et al.)
6. USP 5,262,310, filed 11/16/93 (Karube et al.)
7. USP 5,277,913, filed 01/11/94 (Thompson et al.)
8. USP 4,619,794, filed 10/28/86 (Hauser)
9. USP 5,032,457, filed 07/16/91 (Wallach)
10. USP 4,217,344, filed 08/12/80 (Vanlerberghe et al.)
11. USP 4,483,921, filed 11/20/84 (Cole)
12. USP 4,342,826, filed 08/03/82 (Cole)
13. USP 5,466,467, filed 11/14/95 (Singh)
14. USP 5,190,764, filed 03/02/93 (Chiba et al.)
15. USP 5,000,958, filed 03/19/91 (Fountain et al.)
16. USP 4,812,312, filed 03/14/89 (Lopez-Berestein et al.)
17. USP 5,164,182, filed 11/17/92 (Meybeck et al.)
18. USP 5,128,139, filed 07/07/92 (Brown et al.)
19. USP 5,443,839, filed 08/22/95 (Meybeck)
20. USP 4,708,861, filed 11/24/87 (Popescu et al.)
21. USP 4,485,054, filed 11/27/84 (Mezei et al.)
22. USP 4,978,654, filed 12/18/90 (Lopez-Berestein et al.)
23. USP 4,873,088, filed 10/10/89 (Mayhew et al.)
24. USP 4,663,167, filed 05/05/87 (Lopez-Berestein et al.)
25. USP 5,262,310, filed 11/16/93 (Karube et al.)
26. USP 4,247,411, filed 01/27/81 (Vanlerberghe et al.)
27. USP 4,857,319, filed 08/15/89 (Crowe et al.)
28. USP 4,911,928, filed 03/27/90 (Wallach)
29. USP 4,235,871, filed 11/25/80 (Papahadjopoulos et al.)
30. USP 5,366,881, filed 02/23/93 Singh et al.
31. USP 4,888,288, filed 01/30/86 Wagner
32. USP 5,585,109, filed 08/24/95 Hayward et al.
33. USP 4,533,254, filed 02/21/84 Cook et al.
34. USP 4,721,612, filed 04/10/85 Janoff et al.
35. USP 4,908,154, filed 05/26/87 Cook et al.

between them. If no such English language equivalent is cited, then none is known to the undersigned.


36. EP 0 158 441 A2, 10/16/85
37. JP 57-82311, 11/11/80
38. EP 0 561 424 B1, 03/05/97
39. Hargreaves, W.R. et al., Monoalkyl Liposomes 17(18):3759, 1978
40. Kaler, E.W. et al., Science 245:1371, Sept. 22, 1989

In accordance with MPEP Sections 609 and 707.05(b) it is requested that each document cited (including any cited in applicants' specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing on Form PTO-1449, so that it will appear on the face of the patent issuing on the present application, even if the Examiner does not consider it sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with.

The present Disclosure Statement is also being submitted in compliance with 37 CFR § 1.56 as an Examiner might consider any cited document important in deciding whether to allow the application to issue as a patent, but the citation of each document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents are relevant or effective as prior art, or that they represent the results of a complete search, and it is anticipated that the Examiner in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR §§ 1.104(a) and 1.106(b), and in the course of such search will review for relevance every document cited on the attached form even if not initialed.

Early and favorable consideration is earnestly solicited.

Respectfully submitted,



Anne E. Zitron, Ph.D.

Reg. No. 41,391

Agent for Applicant(s)

DARBY & DARBY
805 Third Avenue
New York, New York 10022
(212) 527-7700